GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qyuns Therapeutics Co Ltd (HKSE:02509) » Definitions » COGS-to-Revenue

Qyuns Therapeutics Co (HKSE:02509) COGS-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Qyuns Therapeutics Co COGS-to-Revenue?

Qyuns Therapeutics Co's Cost of Goods Sold for the three months ended in Dec. 2024 was HK$0.0 Mil. Its Revenue for the three months ended in Dec. 2024 was HK$0.0 Mil.

Qyuns Therapeutics Co's COGS to Revenue for the three months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Qyuns Therapeutics Co's Gross Margin % for the three months ended in Dec. 2024 was N/A%.

Qyuns Therapeutics Co COGS-to-Revenue Historical Data

The historical data trend for Qyuns Therapeutics Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qyuns Therapeutics Co COGS-to-Revenue Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
- - - 0.42

Qyuns Therapeutics Co Quarterly Data
Dec21 Dec22 Sep23 Dec23 Jun24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial - - - - -

Qyuns Therapeutics Co COGS-to-Revenue Calculation

Qyuns Therapeutics Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=71.107 / 169.539
=0.42

Qyuns Therapeutics Co's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qyuns Therapeutics Co  (HKSE:02509) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Qyuns Therapeutics Co's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Qyuns Therapeutics Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Qyuns Therapeutics Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Qyuns Therapeutics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qyuns Therapeutics Co Ltd (HKSE:02509) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:02487 HKSE:01521 HKSE:06996 HKSE:02181 HKSE:06978 HKSE:02563 HKSE:01167 HKSE:01873 HKSE:02566 HKSE:03681 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Website
http://www.qyuns.net
Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory and digestive diseases Key revenue is generated from PRC.
Executives
Tai Zhou Yi Yao Cheng Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Jian Xin Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Hang Zhou Zhong Mei Hua Dong Zhi Yao You Xian Gong Si 2101 Beneficial owner
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Ji Shu Chan Ye Tou Zi Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Qu Hua Yin Jin Rong Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Yuan Da Hua Chuang Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Hua Dong Yi Yao Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Qiu Jiwan
Xu Qiu
Hangzhou Quanyi Investment Management Partnership (general Partnership)
Yu Guo'an
Zhu Jing
Taizhou Xinfu Tongxin Enterprise Management Partnership (limited Partnership)
Sheng Xi Tai

Qyuns Therapeutics Co Headlines

No Headlines